Lumasiran

Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1) [1][2].

Product Specifications

CAS Number

[1834610-13-7]

Product Name Alternative

ALN-G01

UNSPSC

12352208

Target

Glycolate Oxidase; Small Interfering RNA (siRNA)

Type

Oligonucleotides

Related Pathways

Epigenetics; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lumasiran.html

Purity

98.77

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

[Lumasiran]

Molecular Formula

C530H712F10N173O320P43S6

Molecular Weight

16339.00

References & Citations

[1]Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81 (2) :277-282.|[2]Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021;384 (13) :1216-1226.